Proteon Therapeutics is a late-stage biopharmaceutical company committed to improving the lives of patients and families affected by kidney and vascular diseases. The Company is developing potentially transformative solutions to address some of the most urgent needs of patients with chronic kidney disease requiring hemodialysis and peripheral artery disease with the goal of redefining how these diseases are treated. Proteon's lead product candidate, Vonapanitase, is a first-in-class, phase 3 investigational drug designed to treat vessel injury that leads to blood vessel blockage and reduced blood flow. These complications can prevent a patient from undergoing life-saving hemodialysis and result in corrective procedures, excess costs and patient trauma.